Rubric Capital Management LP Has $72.57 Million Holdings in OPKO Health, Inc. (NASDAQ:OPK)

Rubric Capital Management LP grew its holdings in shares of OPKO Health, Inc. (NASDAQ:OPK) by 9.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 48,706,640 shares of the biotechnology company’s stock after acquiring an additional 4,284,336 shares during the quarter. OPKO Health accounts for approximately 1.2% of Rubric Capital Management LP’s investment portfolio, making the stock its 20th largest position. Rubric Capital Management LP owned 0.07% of OPKO Health worth $72,573,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Assenagon Asset Management S.A. grew its holdings in shares of OPKO Health by 142.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock valued at $2,227,000 after purchasing an additional 876,272 shares during the last quarter. Y.D. More Investments Ltd acquired a new position in shares of OPKO Health during the second quarter worth $1,840,000. PFG Investments LLC increased its holdings in shares of OPKO Health by 10.4% during the third quarter. PFG Investments LLC now owns 1,061,090 shares of the biotechnology company’s stock worth $1,581,000 after buying an additional 100,125 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of OPKO Health in the 2nd quarter valued at $592,000. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of OPKO Health by 4.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company’s stock valued at $536,000 after acquiring an additional 17,671 shares in the last quarter. Institutional investors own 64.63% of the company’s stock.

Insider Activity at OPKO Health

In other news, CEO Phillip Md Et Al Frost bought 280,183 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was acquired at an average price of $1.50 per share, with a total value of $420,274.50. Following the completion of the purchase, the chief executive officer now directly owns 211,512,405 shares of the company’s stock, valued at approximately $317,268,607.50. This represents a 0.13 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Insiders have purchased 480,183 shares of company stock worth $741,275 over the last ninety days. Insiders own 47.26% of the company’s stock.

OPKO Health Trading Down 4.3 %

Shares of OPK stock opened at $1.55 on Wednesday. OPKO Health, Inc. has a 1-year low of $0.85 and a 1-year high of $1.75. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The stock has a 50-day moving average of $1.52 and a 200-day moving average of $1.45.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on OPK. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research note on Thursday, September 26th. Piper Sandler reiterated an “overweight” rating and set a $3.00 target price on shares of OPKO Health in a research report on Tuesday, September 17th. Finally, Barrington Research reissued an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a report on Friday, November 8th.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.